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Summary.-Theresponse of14 mousetumour sub-linestotheradiosensitizing action
of a large single dose of misonidazole (MISO) has been assessed by regrowth delay.
In 13 of these, significant enhancement of radiation effect occurred under ambient
conditions, indicating sensitization of naturally hypoxic cells. The enhancement ob-
served (SER') varied with the radiation dose, as would be predicted for a mixed
oxic/hypoxic cell population. The maximum SER' in these 13 tumours did not depend
on histology or regrowth rate.
The 14th tumour, a slow-growing sarcoma, was not sensitized under ambient
conditions, but showed marked sensitization when clamped to produce acutely
hypoxic cells. This is consistent with no hypoxic cells occurring naturally in a
sarcoma with a slow rate of growth. Faster-growing variants ofthis tumour showed
radiosensitization under ambient conditions.
The slow-growing carcinoma, RH, however, appears to contain hypoxic cells and
did show sensitization.
The cytotoxicactionofMIS0wascomparedwiththeradiosensitization byadminis-
tering it after irradiation in 8 of the tumour lines. In 2 tumours no cytotoxicity was
observed. In the rest cytotoxicity was significant, but much smaller than the sensi-
tization observed when MISO was administered before irradiation.
These regrowth-delay data have been used to calculate hypoxic fractions in 3 ways.
Estimates of hypoxic fraction ranged from <0-1% in the slow sarcoma to >30%
in several tumours. There is considerable variation in the estimate, according to the
technique used.
THE 2-nitromidazole misonidazole
(MISO) has become widely used, both ex-
perimentally and in clinical trials, since it
wasfirstshowntobeaneffectiveradiosensi-
tizer of hypoxic cells in vitro and in vivo
(Asquith et al., 1974; Denekamp et al.,
1974). Radiosensitization is a consequence
of the compound's electron affinity, and
in this way it mimics the effect of oxygen
(Asquith et al., 1974; Adams et al., 1976).
MISO has been shown to sensitize hypoxic
cells in vitro but to have no effect on well-
oxygenated cells. For this form of radio-
sensitization the drug must be present at
the time of the ionizing event, the degree
of radiosensitization being dependent on
the local drug concentration (Asquith et
al., 1974; McNally et al., 1978a).
*Studies with experimental tumours,
using a variety of assay techniques, have
demonstrated that radiosensitization of
naturally hypoxic tumour cells can also
be achieved invitro (seeProceedings of 8th
L. H. Gray Conference, 1978). McNally
et al. (1978a) showed that the same degree
of sensitization can be achieved in tumour
cells in vivo, as can be achieved for Chinese
hamster V79 cells in vitro, for a range of
local drug concentrations. The time
between administration of the drug and
irradiation may be critical in the mouse,
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of the drug to the tumour cells and the
compound's short half life in the mouse
(t+=1-1b5 h) (Flockhart et al., 1978).
The optimum interval varies from 15 to
60 min in different experimental tumours
(McNally et al., 1978b; Fowler & Dene-
kamp, 1979). The proportion of well-
oxygenated to hypoxic cells in the tumour
will also influence the observed sensitizer
enhancement ratio (SER') since at low
radiation doses the tumour response is
dominated by the oxic rather than the
hypoxic cells (Denekamp & Harris, 1975;
Denekamp et al., 1977).
In addition to theradiosensitizing action
ofMISO, there is a direct cytotoxic action,
which is also specific for hypoxic cells
(Sutherland, 1974; Hall & Roizin-Towle,
1975). The magnitude of this effect in
human tumours is difficult to predict,
butithasbeenshown to be small compared
with the radiosensitization in both mouse
and man (Denekamp, 1978; Denekamp &
McNally, 1978).
This paper summarizes experimental
data on the sensitizing action of MISO on
aerobic tumours, assessed using a single
assay method (regrowth delay) in 14
different tumour sublines. Several of these
tumours have also been studied under
conditions ofuniform hypoxia, induced by
occluding the blood supply with a clamp.
In addition, the direct cytotoxic action of
the drug has been tested by administering
it shortly after irradiation in 8 of the
tumours. A small proportion of these data
has been previously published, but is
included here to provide a'comprehensive
comparison.
MATERIALS AND METHODS
The regrowth-delay assay and the irradia-
tion procedures which were used in these
experiments have been described previously
(e.g. Denekamp & Harris, 1975; Sheldon &
Hill, 1977). The original 6 tumours all arose
spontaneously in mice of the CBA/Ht or
WHT/Ht strain in our laboratory and have
been maintained by s.c. passage in strictly
isogeneic mice. The tumour responses are
thereforebelieved tobefreeoftransplantation
artefacts. The sarcomas were derived from 3
original spontaneous tumours; differences in
their radiation response and/or their growth
rates have been observed with successive
transplantation (see Table I).
TABLE I.-Some biological characteristics of the tumiours
Tumour origin
Spont. 1975
Spont. 1966
Spont. 1968
From Ca NT 1975
Spont. 1962
From SAS 1975
From SAS 1977
From SAS 1977
From SAS 1975
From SAS 1975
Spont. 1973
From SAFA 1976
From SAFAa 1978
Spont. 1967
Volume
doubling
time
(days)
10-3
12-0
2-8
2-8
12-4
5 0
5-8
9.7
3-3
7-8
2-7
2-8
3-8
3-5
Tumour
Treatment Regrowth
size size
(mm) (mm)
8-5
8-5
8-5
8-5
8-5
8-5
7-5
7-5
8-5
7-5
7-5
7-5
7-5
7-5
12
10
10
10
10
10
9
9
12
10
12
12
12
12
* Data previously published in whole or in part (Denekamp & Harris, 1975; McNally et al., 1978b;
Denekamp & Stewart, 1978).
t A =X-rays, ambient conditions; B =X-rays after MISO; C =X-rays before MISO; D =X-rays to
clamped tumours; E =X-rays to clamped tumours after MISO.
t Specific-pathogen-free animals derived by fostering on BSVS mothers, i.e. WHTfBv mice.
Tumour
Carcinomas
DA DC
CA RH
*CA NT
CA NTa
Sarcomas
SA S
SA Sa
SA Sb
SA Sc
FFS 1
FFS 2
*SA FA
*SA FAa
tSA FAb
*BS 2b
Mouse
strain
CBA
WHT
CBA
CBA
CBA
CBA
CBA
CBA
CBA
CBA
WHT
WHT
WHT
WHT
Year
of
expts
1976-7
1976-8
1973-4
1975-6
1975-6
1975-6
1977
1977-8
1976
1976
1974-5
1976-8
1978-9
1974-5
Treatments
usedt
A.B.C
A,B,C,D,E
A,B,C,D,E
A,B
A,B,D,E
A,B,D
A,B
A,B
A,B,C
A,B,C
A,B,D,E
A,B,C,D
A,B,C
A,B,C
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Tumours were implanted s.c. into batches
of 100-250 male mice (aged 2-3 months) and
irradiated on a 250 kVp Pantak X-ray set
operating at 240 kV, 15mA, with a half-value
layer of 1-3 mm Cu and a dose-rate of 2 or 4
gray/min. Unless otherwise stated, the mice
were anaesthetized with sodium pento-
barbitone, using 60 mg/kg for X-rays alone,
or 40 mg/kg for X-rays plus MISO, because
ofthe combined soporific and toxic effects of
the two drugs. Details of the tumour growth
rates, the size at irradiation and the size at
which regrowth delay was assessed are sum-
marised in Table I. In general sarcomas con-
tinued to grow for several days before slowing
their growth rate or shrinking (Denekamp,
1972); hence a larger size was often used for
the assay of regrowth delay in sarcomas
(Table I).
When tumours were clamped for irradia-
tion, to render the cells uniformly hypoxic,
this was achieved with a metal D-shaped
clamp applied across the base of the tumour
at least 10 min before and during irradiation.
MISO (kindly provided by Dr C. E. Smithen
of Roche Products Ltd, Welwyn Garden
City) was always used as a fresh solution,
made up in sterile saline at a concentration of
30 mg/ml. One mg/g body weight was
administered to each mouse i.p. 15 or 30 min
before irradiation or application ofthe clamp.
After treatment the tumours were measured
with vernier calipers in 3 dimensions to obtain
the geometric mean diameter. The frequency
of measurement was decided on the basis of
the growth rates, and ranged from 5 times a
week for the BS2b tumours to once or twice
a week for CA RH and slow SA S.
RESULTS
The regrowth time from irradiation to a
fixed size (see Table I) was measured for
each individual tumour. The mean and
standard error (s.e.) for each dose group
of 8-15 tumours is plotted as a function of
radiation dose in Figs 1-4. If an animal
was cured or died without the tumour
reaching the regrowth size, provided the
animal was killed after the mean regrowth
time for that dose group, it was included
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FIG. 1.-Dose-response curves for tumours
clamped to occlude the blood supply and to
render all the cells hypoxic. Time to grow
from irradiation to the assay size (see
Table I for details) is plotted as a function
of radiation dose. * =X-rays alone.
A =X-rays 15-30 min after 1 mg/g MISO.
All 4 tumours show significant radiosensit-
ization at all dose levels. SER values are
indicated against the curves. Each point
represents the mean + s.e.
in the analysis, and the error bar has an
upward arrow, showing that this is a
minimum estimate of regrowth delay.
Fig. 1 shows the response of tumours
clamped to make all the cells uniformly
hypoxic. Under these conditions a smooth
curve was obtained for the tumours
treated with X-rays alone, indicating a
uniform radioresistance. When 1 mg/g
MISOwasadministeredbeforeirradiation a
greater radiosensitivity was observed; the
curves were displaced to the left. The
degree of sensitization can be quantified
as an SER (sensitizer enhancement ratio)*
by comparing doses to give an equal level
of tumour delay without and with the
drug. The observed SER' for aerobic
*SER=-_dose X-rays without drug to achieve the same level of radiation effect in fully hypoxic cells. dose X-rays with drug
SER' =ditto for a mixed population ofoxic and hypoxic cells.
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TABLE II.-Sensitization and cytotoxicity
of MISO in aerobic and clamped
tumours
SER
(clamped)
1 mg/g
15 min
MIS before
treatment clamping
Carcinomas
CA DC
CA RH
CA NT
CA NTa
Sarcomas
SA S
SA Sa
SA Sb
SA Sc
FFS 1
FFS 2
SA FA
SA FAa
SA FAb
BS 2b
SER' DMF
(aerobic) posUt-eecUt) V
1 mg/g 1 mg/g
n
5-30 min 5 min
before after
X-rays irradiation
1-7 1-2
1-8 1-4
2-2 1-2 0
2-1 -
0
<1-1 -
1-3 w
1-6 F
2-0
1-8
1-5
2-0
1-8
2-4
1-7
1-0
<1-2
1-2
1-3
<1-0
1
2-0
2-0
2-0
2-2
The values shown have been derived from the top
of each pair of curves in Figs 1-4. - data not
available.
tumours is likely to be lower than the
maximum SER. Under clamped conditions
the SER does not vary much, regardless of
dose level, because the cells have all been
madehypoxic. Values ofSER areindicated
in Fig. 1 and summarised in Table II. The
SER values are closely similar for the 4
different tumours (2-0-2-2).
Figs 2 and 3 show the results for the
4 carcinomas and the 10 different sarcoma
linesirradiatedunderambient (unclamped)
conditions. In all the tumours except
SA S, significant radiosensitization was
foundwhenMISO was administered before
irradiation. The dashed lines represent the
clamped data reproduced without data
points.
In Fig. 2 the curves for carcinomas
treated with X-rays alone (mice breathing
air and with no clamp) are all to some
extent biphasic, with "break points" dis-
cernible at 10-20 gray. The initial response
is believed to be that of the well-oxygen-
ated tumour cells; the response at higher
doses becomes progressively dominated by
the naturally hypoxic tumour cells, and
RADIATIO DOSE (GRAY)
FIG. 2.-Dose-response curves for 4 car-
cinomas irradiated under aerobic condi-
tions. &=X-rays alone. *=X-rays plus
MISO. The dashed lines are for clamped
tumours (without drug) from Fig. 1. Each
point is the mean+ 1 s.e. of 8-15 tumours.
Sensitization is seen in all 4 tumours. The
SER' increases with increasing radiation
dose.
deviates towards the hypoxic curve, which
is reproduced as a dashed line from Fig. 1.
The tumours irradiated after MISO ad-
ministration are more sensitive and give a
smooth curve, displaced to the left. SER'
values vary with the level of tumour
delay, being greater at higher radiation
doses. This is exactly what would be
predicted from cell-survival curves for
mixed oxic/hypoxic cell populations (e.g.
Denekamp & Harris, 1975; Denekamp
et al., 1977). At the high dose levels the
SER' values range from 1-7 to 2-2 for the
4 carcinomas (Table II).
In Fig. 3 a similar result can be seen for
most of the sarcomas. Although the
"break points" are not always so pro-
minent, the curves diverge with increasing
dose, indicating a larger SER' at the
higher radiation doses. Two of these sets
of data were obtained for tumours im-
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FIa. 3. Dose-response curves for the 10 sarcomas irradiated under aerobic conditions. The dashed
lines represent the response ofclamped tumours for comparison. Significant sensitization, increasing
with increasing dose, is seen in all tumours except the original version ofthe slow SA S. Each point
represents the mean + s.e. of 8-10 tumours. Upward arrows indicate loss of an animal before the
regrowth size had been reached (see text).
planted on the back and irradiated without
anaesthetic (SA Sb, SA Sc) whereas all
other tumours were implanted on the
chest and the mice were anaesthetized for
irradiation. The original slow SA S is
exceptional, inthatthere is noclearsepara-
tion of the points for tumours irradiated
under aerobic conditions with or without
the drug. Both curves are displaced well
to the left of the curve for clamped
tumours (dashed line). This is believed to
be due to an absence of hypoxic cells in
the original version of this slow-growing
sarcoma. In all the subsequent variants
(SA Sa, SA Sb, SA Sc, FFS 1 and FFS 2)
with faster growth rates (Table I) sig-
nificant sensitization was found. The ori-
ginal tumour, however, waS sensitized
if it was irradiated under clamped,
hypoxic conditions (Fig. 1); the curve for
clampedtumourssensitizedwithMISO can
be super-imposed upon the aerobic curves
with or without MISO. Thus in this, as in
all other tumours, when hypoxic cells are
present the compound is similarly effective
as a radiosensitizer (SER = 2 0).
Fig. 4 demonstrates the cytotoxicity
when MISO was administered shortly after
irradiation. Data points are shown only
for animals injected with 1 mg/g MISO
5 min after irradiation: the curves are
reproduced without data points from
Figs 2 and 3 for X-rays alone, or with the
sensitizer given before irradiation under
ambient conditions. The extent to which
post-irradiation MISO influenced tumour
delayvaried considerably from one tumour
to another.
In tumours FFS 1 and BS 2b there was
clearly no additional regrowth delay for
tumours irradiated with X-rays alone and
given 1 mg/g MIS post-irradiation. In the
other tumours the data points fall between
the curves for X-rays alone and for X-rays
after administration of the sensitizer.
Thus a cytotoxic post-effect was detectable
in 6 ofthe tumours, but was much smaller
in magnitude (DMF= 1.2-1 4) than the
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FIG. 4.-The cytotoxic action of AIISO. The data points (± s.e.) represent groups of 8-10 mice given
1 mg/g MIS 5 min after irradiation. The solid lines are for X-rays alone, andl the dashed lines for
MISO before X-rays, redrawn from Figs 2 and 3. A cytotoxic post-irradiation effect is seen in most
of the tumours, as an increase in tumour delay relative to X-rays alone. It is much smaller tlhan the
effect observed when AIISO is given before irradiation (dashed lines).
full effect seen with the drug given first
(SER'= 1.5-2.4).
DISCUSSION
These tumour data show that a large
degree of radiosensitization was observed
in a wide range of tumour types, in which
hypoxic cells were present naturally or
were induced by occlusion of the blood
supply. The degree of sensitization in
tumours irradiated under aerobic condi-
tions was generally dose dependent, being
low at low radiation doses and increasing
with increasing damage (i.e. at higher
doses). Sensitization was seen both with
and without anaesthetic. The only tumour
in which no significant effect was seen
under aerobic conditions was the original
slow SA S. However, a large SER was
observed for this tumour, as for the
others, when it was irradiated under
clamped conditions. This is interpreted as
being because a negligible proportion of
naturally hypoxic cells was present in the
tumour in its original slow-growing form.
The low proportion, or absence, of
hypoxic cells in the original tumour may
relate to its slow growth rate; it had a
potential doubling time of -250 h
resulting from a mean cell-cycle time of
50 h and a growth fraction of 20%
(Denekamp, unpublished). This slow rate
of cell production and the small cell-loss
factor resulted in a volume-doubling time
ofabout 12 days. This slow cell production
may have allowed the vasculature to keep
pace with the increase in tumour mass,
and may be the reason why no regions of
hypoxia developed. In the later, more
rapidly growing versions of the tumour,
hypoxic cells appear to be present in
tumours irradiated under aerobic condi-
tions and these are amenable to sensitiza-
tion. Thus it is clear that it is not the
tumour-cell type that prevent our
observing an effect in the original SA S
experiments, but rather the presence or
absence of hypoxia.
The equally slow CA RH and the slow
lil 0
R.
.
WI.
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CA DC do show radiosensitization under
aerobic conditions (Fig. 2). The cell-
proliferation kinetics of these tumours are
not yet available, but other studies have
shown that slow growth in carcinomas is
usually a result ofextensive cell loss rather
than slow cell production (Denekamp,
1970, 1972). In this case the vasculature
may be incapable ofsupplying an adequate
oxygen level to all the tumour cells,
resulting in naturally occurring, hypoxic,
radio-resistant cells.
At high radiation doses, the degree of
radiosensitization of aerobic tumours ap-
proaches that when the tumours are
clamped (Table II). This is consistent with
hypoxic cells dominating the response as
more cell killing occurs (Denekamp &
Harris, 1975). It demonstrates that natur-
ally hypoxic cells and those made acutely
hypoxic are equally accessible to the drug,
and that the effect of the radiosensitizer
is not being measurably limited by dif-
fusion.
The reason for the slightly different
maximum SER' values in the different
tumours is not known. These could result
from differences in drug availabilitv at the
sites of the hypoxic cells in different
tumours, but the clamped vs aerobic
tumour comparisons make this seem
unlikely. Alternatively it could reflect
differences in the intrinsic response of
different cell lines to the same drug
concentration, as has been observed in
vitro (McNally et al., 1978a).
All the tumours were irradiated at 15
or 30 min after the same drug dose (1 mg/
g). However, the serum level achieved in
the two mouse strains differs, being
1f4 mg/ml for CBA and 1 mg/ml for WHT
mice of equal size (- 30g) after 1 mg/g
administered (Denekamp et al., unpub-
lished). This is unlikely to account for the
differences observed, because the wide
variations in SER' have been found in the
two later versions of the fibrosarcoma,
which of course are in the same strain of
mice. The concentration of drug at the
site of the hypoxic cells in these tumours
is unfortunately unknown.
A major factor which will influence the
measured SER' is the hypoxic fraction.
The hypoxic fractions can be calculated
for these tumours in three ways:
(A) By looking at the changing SER'
with dose per fraction, if a maxi-
mum SER value is known, or can be
deduced.
(b) By comparing the aerobic and
hypoxic response (Thomlinson &
Craddock, 1967).
(C) By converting the regrowth-delay
curves into "pseudo cell survival
curves" and extrapolating back
from the break point (Denekamp &
Harris, 1975).
The first approach has been usedforhuman
tumour data (Denekamp et al., 1977) and
the technique is described in more detail
in another paper in preparation (Dene-
kamp et al.).
The hypoxic fractions calculated in
these three ways are summarised in Table
TABLE III.-Estimates of hypoxic fraction
for 14 mouse tumours
Method-~~~~A
Caorcinomas
CA DC
CA RH
CA NT
CA NTa
Sarcomas
SA S
SA Sa
SA Sb
SA Sc
FFS 1
FFS 2
SA FA
SA FAa
SA FAb
BS 2b
A
- 10%
15%
,20%
0%
l4%
, 10%
,.3%
1.5%
>50%
000
'50%
l.5%
B C
25%
18%
30%
15%
7%
5%
< 0-01% 0% 40, 10%
8%
30%
1%
20%
700° 30%
20% 5%
_ 23%
-25%
A. From cell-survival curves constructed for a
mixed population of oxic and hypoxic cells to give
an SER' estimate at 10 Gy. Assumptions: OER=
2-7, SER=2-0, Do=135, n=-20, initial/final slope
ratio = 3.
B. From the vertical displacement of the aerobic
and clamped lines (assuming one doubling time ofthe
tumour corresponds to a factor of 2 in cell killing).
C. By extrapolation of the "breakpoint" on the
aerobic curves back to zero dose, and constructing
"pseudo survival curves" as in Denekamp & Harris
(1975).
- data not available.
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III. The values range from < 0 01% in the
original slow sarcoma SA S, to 30% in
several of the tumours. The values vary
considerably when estimated by the dif-
ferent techniques. They should be similar
when calculated by methods B and C, but
usually give lower estimates by method A,
which is the only technique that can be
applied to clinical data (Denekamp et al.,
1977). Thus the clinical estimates of
hypoxic fractions may also be under-
estimates.
The extent of post-irradiation cyto-
toxicity was markedly different in the 8
tumours studied (Fig. 4). Two tumours
had no apparent cytotoxic effect, whereas
the others showed a variable extra delay
in regrowth due to administration of the
drug shortly after irradiation. This in-
creased delay is attributable to direct
cytotoxic action of the drug. It may be
specifically due to anaerobic metabolism
of the MISO to a more toxic reduced
product which may be lethal to the
hypoxic cellsthemselvesortoneighbouring
oxic cells. The cvtotoxic effect was not
very large, corresponding at most to a
dose-modifying factor of 1-4 or an extra
decade ofcellkill. Thisismuchsmallerthan
the effect predicted from the in vitro
experiment designed to simulate the
serum concentration and half life in the
mouse (Stratford & Adams, 1978). It
has been shown for in vitro experiments
that there is a considerable threshold
time of exposure before cell killing occurs,
and that this is dose dependent (Stratford
& Adams, 1976; Hall et al., 1978). As has
been discussed previously (Denekamp,
1978) the small size of the effect in mouse
tumours may result from the short half
life in the mouse (1-1- h) or the rapid
turnover of hypoxic cells in the tumour.
Cells which are acutely hypoxic only for
the duration of irradiation (e.g. as a result
of periodic opening and closing of blood
vessels) may be more important to the
radiation response than cells which are
chronically hypoxic at a maximum dis-
tance from the capillaries (Yamaura &
Matsuzawa, 1979; Brown, 1979). Such
transiently hypoxic cells would not be
exposed to the drug in a hypoxic environ-
ment for long enough to allow full expres-
sion of the anaerobic metabolism and
hence cytotoxicity. However, all efforts to
overcome the problem of a short half life
(by nephrectomy to prevent excretion,
by repeated injections of drug or by con-
tinuous infusion) have proved incapable
of demonstrating a much larger cytotoxic
effect in mice (Brown et al., 1979; Pedersen
et al., 1979). This is consistent with deduc-
tions of minimal cytotoxicity from the
scanty human data that are available,
where the longer halflife in man (10-18 h)
should permit the full cytotoxic effect
(Denekamp & McNally, 1978).
In summary, the radiosensitizing ability
of MISO when tested with a single assay
of tumour response is similar in a wide
range of tumours. Hypoxic cells, when
present naturally or as a consequence of
occluding the blood supply, are accessible
to MISO and are sensitized by it to a large
extent. The extent of radiosensitization
at any dose level is dependent on the
proportion ofhypoxic cells in the tumour,
but at high doses the values obtained in
aerobic tumours are close to those in fully
hypoxic (clamped) tumours. The post-
irradiation effect ofMISO is either absent,
or much smaller than the full radiosensi-
tizing effect, in these mouse tumours.
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